WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
WEST PHARMACEUTICAL SERVICES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$383.91−0.11 (-0.03%)
Close on Oct 19, 2026
- Market cap
- $27.37B
- P/E (TTM)
- 49.2
- Dividend yield
- 0.22%
WEST PHARMACEUTICAL SERVICES INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $2.49B | $2.33B | $2.40B | $2.41B | $2.32B | $1.65B | $1.40B | $1.31B | $1.24B | $1.19B | 81.1% | +6.8% |
| Contract-Manufactured Products | $582.00M | $558.70M | $552.50M | $480.40M | $514.70M | $498.60M | $441.50M | $409.10M | $362.50M | $320.20M | 18.9% | +4.2% |
| Contract-Manufactured Products [Member] | – | – | – | – | – | – | – | – | $362.50M | $320.20M | – | – |
| Corporate [Member] | – | – | – | – | – | – | -$200.00K | -$300.00K | -$300.00K | -$1.00M | – | – |
| Intersegment sales elimination | – | – | – | – | – | – | -$200.00K | -$300.00K | -$300.00K | -$1.00M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $657.20M | $577.80M | $710.10M | $784.40M | $796.10M | $434.50M | $313.60M | $266.40M | $243.80M | $243.10M | +13.7% |
| Contract-Manufactured Products | $63.40M | $72.30M | $72.10M | $60.40M | $67.20M | $68.60M | $49.10M | $44.30M | $48.30M | $38.20M | -12.3% |
| Contract-Manufactured Products [Member] | – | – | – | – | – | – | – | – | $48.30M | $38.20M | – |
| Corporate [Member] | – | – | – | – | – | – | -$66.10M | -$70.40M | -$66.30M | -$86.10M | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.33B | $1.23B | $1.24B | $1.29B | $1.20B | $975.60M | $814.70M | $766.10M | $734.60M | $738.30M | 43.3% | +8.0% |
| Other European countries | $451.00M | $385.50M | $388.10M | $359.20M | $341.30M | $236.80M | $251.10M | $230.50M | $201.00M | $268.30M | 14.7% | +17.0% |
| Germany | $380.30M | $372.50M | $406.10M | $398.70M | $474.30M | $282.10M | $236.30M | $235.90M | $226.40M | $200.60M | 12.4% | +2.1% |
| Other | $353.30M | $339.00M | $348.50M | $364.30M | $357.40M | $253.70M | $213.40M | $201.80M | $194.00M | $185.60M | 11.5% | +4.2% |
| Ireland | $333.30M | $323.20M | $285.70M | $240.30M | $247.60M | $226.00M | $173.80M | $138.10M | $100.50M | – | 10.8% | +3.1% |
| France | $226.60M | $242.20M | $282.90M | $237.90M | $213.00M | $172.70M | $150.60M | $145.00M | $142.60M | $116.30M | 7.4% | -6.4% |
From the segment and revenue-disaggregation notes of West Pharmaceutical Services's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.